Nonsteroidal antiinflammatory drugs (NSAIDs) appear to reduce the risk of developing
cancer. One mechanism through which NSAIDs act to reduce carcinogenesis is to inhibit the …

The cyclo-oxygenase (COX) metabolic pathway and prostaglandin (PG) production appear
to play a causal role in the promotion and progression of human cancers. COX-1 and COX-2 …

Tumorigenesis is a complex process, and understanding the mechanisms behind
tumorigenesis is key to identifying effective targeted therapies. Prostaglandins are signaling …

Inhibitors of the inducible cyclooxygenase (COX‐2) have emerged as a promising new class
of drugs that may be useful for the prevention of colorectal cancer. Experimental evidence to …

The existing epidemiologic literature was comprehensively reviewed to retrieve all
epidemiologic studies (case control and cohort studies) that examined exposure to …

Abstract Cyclooxygenase2 (COX-2), an inducible prostaglandin G/H synthase, is
overexpressed in several human cancers. Here, the potential utility of selective COX-2 …

Abstract Cyclooxygenase-2 (COX-2) is an inducible enzyme that regulates prostaglandin
synthesis and is overexpressed at sites of inflammation and in several epithelial cancers …

COX-2 is upregulated at an early stage in colorectal carcinogenesis and generates
prostaglandins, which promote cancer cell proliferation, impair apoptosis and enhance …

Epidemiologic studies have documented a 40–50% reduction in incidence of colorectal
cancer in individuals taking nonsteroidal antiinflammatory drugs (NSAIDs). Since NSAIDs …

Several lines of evidence suggest that the cyclooxygenase enzymes (specifically COX-2)
might be an important molecular target for the intervention of cancer at both early and late …